AstraZeneca cuts Alexion's PhIII Wilson disease drug, takes $244M writedown
AstraZeneca is calling it quits with a Phase III rare disease program it obtained via the $39 billion acquisition of Alexion.
ALXN1840, or bis-choline tetrathiomolybdate, had in turn come to Alexion from a buyout. In 2018, Alexion offered $855 million in cash to acquire Wilson Therapeutics for the candidate, designed to treat Wilson disease — a rare condition where patients can’t remove copper from the body, resulting in excessive amounts of copper accumulating in the liver, brain and eyes.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.